These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37240667)

  • 1. Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria.
    Bernstein JA; Giménez-Arnau A; Maurer M; Staubach P; Barbier N; Hua E; Severin T; Laires PA; Balp MM
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria.
    Giménez-Arnau A; Maurer M; Bernstein J; Staubach P; Barbier N; Hua E; Severin T; Joubert Y; Janocha R; Balp MM
    Clin Transl Allergy; 2022 Feb; 12(2):e12121. PubMed ID: 35218324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria.
    Metz M; Bernstein JA; Giménez-Arnau AM; Hide M; Maurer M; Sitz K; Soong W; Sussman G; Hua E; Barve A; Barbier N; Balp MM; Severin T
    World Allergy Organ J; 2022 Nov; 15(11):100716. PubMed ID: 36440464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
    Kolkhir P; Laires PA; Salameh P; Asero R; Bizjak M; Košnik M; Dissemond J; van Doorn M; Hawro T; Kasperska-Zajac A; Zajac M; Kocatürk E; Peter J; Parisi CAS; Ritchie CA; Kulthanan K; Tuchinda P; Fomina D; Kovalkova E; Khoshkhui M; Kouzegaran S; Papapostolou N; Du-Thanh A; Kamegashira A; Meshkova R; Vitchuk A; Bauer A; Grattan C; Staubach P; Bouillet L; Giménez-Arnau AM; Maurer M; Weller K
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.
    Rossi O; Piccirillo A; Iemoli E; Patrizi A; Stingeni L; Calvieri S; Gola M; Dapavo P; Cristaudo A; Zichichi L; Losappio L; Saccheri F; Pastorello EA
    World Allergy Organ J; 2020 Dec; 13(12):100470. PubMed ID: 33343800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
    Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
    World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of symptomatic patients with chronic spontaneous urticaria: a real-world study in Korea.
    Ye YM; Koh YI; Choi JH; Kim MA; Park JW; Kim TB; Nam YH; Chang YS; Park HS
    Korean J Intern Med; 2022 Sep; 37(5):1050-1060. PubMed ID: 36068718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotic as an adjuvant therapy in chronic urticaria: a blinded randomized controlled clinical trial.
    Atefi N; Fallahpour M; Sharifi S; Ghassemi M; Roohaninasab M; Goodarzi A
    Eur Ann Allergy Clin Immunol; 2022 May; 54(3):123-130. PubMed ID: 33939347
    [No Abstract]   [Full Text] [Related]  

  • 10. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study).
    Lacour JP; Khemis A; Giordano-Labadie F; Martin L; Staumont-Salle D; Hacard F; Tian H; McBride D; Hollis K; Hunter S; Martin L; Lamirand A; Le Guen S; Balp MM; Berard F
    Eur J Dermatol; 2018 Dec; 28(6):795-802. PubMed ID: 30698148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H
    Chu CY; Al Hammadi A; Agmon-Levin N; Atakan N; Farag A; Arnaout RK; Kannenberg S; Kulthanan K; Mubarak A; Zaitoun F; Crowe S; Malfait S; Cooke K; Dekker EL
    World Allergy Organ J; 2020 Apr; 13(4):100117. PubMed ID: 32382379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
    Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
    Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
    Finlay AY; Kaplan AP; Beck LA; Antonova EN; Balp MM; Zazzali J; Khalil S; Maurer M
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1715-1721. PubMed ID: 28573683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.
    Maurer M; Abuzakouk M; Bérard F; Canonica W; Oude Elberink H; Giménez-Arnau A; Grattan C; Hollis K; Knulst A; Lacour JP; Lynde C; Marsland A; McBride D; Nakonechna A; Ortiz de Frutos J; Proctor C; Sussman G; Sweeney C; Tian H; Weller K; Wolin D; Balp MM
    Allergy; 2017 Dec; 72(12):2005-2016. PubMed ID: 28543019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Immunosuppressants and Biological Therapy for Chronic Spontaneous Urticaria: A Network Meta-Analysis.
    Lin WK; Lin SJ; Lee WR; Lin CC; Lin WC; Chang HC; Cheng CT; Hsu JC
    Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations.
    Tawil S; Irani C; Kfoury R; Salameh P; Baiardini I; Weller K; Maurer M; Ezzedine K
    Int J Dermatol; 2020 Aug; 59(8):893-901. PubMed ID: 32638368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study.
    Thomsen SF; Pritzier EC; Anderson CD; Vaugelade-Baust N; Dodge R; Dahlborn AK; Vestergaard C
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1048-1055. PubMed ID: 28294420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases.
    Subramaniyan R; Chopra A
    Indian J Dermatol; 2016; 61(4):467. PubMed ID: 27512204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.